LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of investors of Juno Therapeutics, Inc. (“Juno” or the “Company”) (NASDAQ: JUNO) concerning the Company and its officers’ possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors.
Juno is a biopharmaceutical company that engages in the development of cell-based cancer immunotherapies. The Company specializes in its chimeric antigen receptor and T cell receptor technologies that are designed to genetically engineer T cells to recognize and kill cancer cells.
On July 7, 2016, post-market, Juno disclosed that three patients had passed away during a clinical trial for the Company's chemotherapy drug, fludarabine.
On this news, Juno's share price has fallen over 32% to just $27.70 during intra-day trading on July 8, 2016.
If you purchased Juno securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to firstname.lastname@example.org, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.